ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SALV Salvarx Group Plc

4.50
0.00 (0.00%)
18 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Salvarx Group Plc LSE:SALV London Ordinary Share IM00BZ4SS228 ORD 2.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4.50 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Salvarx Share Discussion Threads

Showing 1 to 12 of 600 messages
Chat Pages: Latest  12  11  10  9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
22/3/2016
09:34
The fact that Oxfolrd University is funding the first human trial and the involvement of the Ludwig Cancer Institute which has relationships with Universities and science labs across America and Europe is impressive.
wiseacre
21/3/2016
23:38
I only chose selected aim stocks. The names involved here are serious players who know their stuff. Their timing is also correct. One of those stocks that could really move on momentum. I can only dream of the valuation on a commercialiality. Li£e changing sum imo.
kmann
21/3/2016
13:16
The Company is pleased to announce that, at the General Meeting held earlier today, all the resolutions proposed were duly passed, with Resolution 2, to waive the obligation of the Concert Party to make a mandatory general offer which would otherwise be required under Rule 9 of the Takeover Code, being conducted on a poll of Independent Shareholders.

Following the resolutions being passed, the Company's name will be changed to SalvaRx Group plc and the acquisition of the issued share capital not already owned by it in SalvaRx Limited, for an aggregate consideration of £8.8 million, to be satisfied by the issue of New Ordinary Shares, as more particularly described in the Admission Document, is expected to occur at 8.00 a.m. on 22 March 2016. As from Admission the Company's TIDM will be "SALV".

As previously announced, the Company has raised £1.95 million (before expenses) by way of a Placing of New Ordinary Shares at 35.5p per share in order to fund the Enlarged Group's further development, including its working capital needs.

New Board

Following Admission, Jim Mellon will replace Richard Armstrong as Non-Executive Chairman (with Richard Armstrong continuing as a non-executive director of the Company) and Dr Ian Walters and Kam Shah will be appointed as directors of the Company.

the stigologist
21/3/2016
07:25
Plenty of oppotunity in the $80BILLION indusry. Good call Jim
kmann
20/3/2016
20:30
New dawn for this company.



Press mention today.

Some serious names and money involved. Been some high profile pharmas being bought out in multimillion deals.

Inxestors looking to buy in to the next deco bagger. Thats multi 10 bagger

kmann
05/3/2016
17:56
Agree an excellent post from SK. I have not read the full document yet, but have had a quick skim. I am not sure whether I am up for this yet or not, but there is plenty of time to decide - trading does not start for another 2 weeks.

Blindly following "Britain's Buffett" is not always the right thing to do, he makes mistakes, just like the real Buffett. However it is always worth having a good look at what he is up to - he did not become as rich as he is by being stupid. He has put his own money in here, albeit a relatively small amount compared to his net worth, and he is locked in. I would be surprised if he did not back future fundraises with his own money too.

My only experience of an RTO (MRG became IRON) was that a lot of the shareholders bailed in the first few month and drove the shareprice right down. I was holding MRG before the RTO and it was definitely the shareholders who got free shares from the company which owned the asset that was reversed in that were doing the majority of the selling (they owned the majority of the shares), so it is not exactly the same situation. I was massively underwater with MRG anyway, so just sat there until the selling stopped, averaged down massively at 2p (RTO and placing was done at 6p) and took some profits to get all my money back when they latter hit 15p. They are well down on that now because of the massive drop in commodities prices, but I am on a free ride and happy to sit and wait again.

Obviously there is no guarantee that this pattern will repeat here, there are so many differences in the situation. However what SK says about the relatively limited liquidity and the shell game players wanting to take their profits leads me to expect that shareprice movements in the first few months at least are likely to be downwards. Great even more time to digest fully the admission document and do further research. I think the time to buy might be when we see what happens when a new investment is brought in. It will be another high risk one as SK says, but if Jim Mellon does put up a fair proportion of the cash and all the sellers are out, having reduced the shareprice considerably, then maybe I will overcome my aversion to high risk plays and have a punt.

rec0very stock
05/3/2016
17:56
Great Info Karolina - Thanks, I thought it was considered bad practise for non-execs to have options these days ??
rbcrbc
05/3/2016
14:35
This is quite simply a play on whether you think Jim Mellon knows his onions because he will own about 36% and he can't sell into the market he will need a liquidity event in form of a takeover probably for several billion somewhere down the road.

I will look to buy anywhere below 50p on relist.

the stigologist
05/3/2016
12:41
Great summary thanks, Sweet Karolina.
adred
05/3/2016
12:32
One would expect that once the suspension is lifted the shares will trade (post 100:1 consolidation) at around 33p initially. You are then free to make your own investing decision. Having read the full admission document you are ideally placed to do that and you need no further advice, you have all the info you need.

SalvaRx is a very high risk company. It is investing in things that are sadly far more likely to fail than they are to succeed - cancer would have been cured ages ago, if this were not the case. It has one high risk investment already and is looking to make more high risk investments - it is the have 9 zeros and 1 ten bagger and you break even model. However if the 10 bagger turns into a 100 bagger, then everyone is quids in. They still have to make those other investments for the model to work and they will have to raise money to do that.

In the short term, post lifting of suspension, those who do not like such a high risk play will get out - none of the other investors with notifiable interests took part in the placing. They therefore no longer have notifiable interests, due to the dilution, and can sell as they see fit. They may hold but if they were thinking of buying they would have done so in the placing. Most of those other investors got in for the shell game phase and not for the post RTO phase. Just under 75% of the shares are locked in. Just over 15% are the placing shares, which have not gone to bucket shops, but, one assumes, to long term investors who, one would presume, read and understood the admission document and are happy to play in such high risk investments. So only about 10% of the shares are really in play, which will make liquidity tight - big spreads, big drops on sells, but also big rises on buys. A hard game to play and make money on, in the short term. The trading performance will have a big impact on what future fundraisings are achieved at - if there are no future fundraisings SALV remains a one trick pony in a very high risk environment.

You will note from your reading of the full admission document that of the various milestones, which had dates against them, none have been achieved and most of those dates are in the past - not a huge surprise as that is the nature of the business. You can see what the milestones are and when they are eventually achieved an RNS will be released saying the milestone has been achieved and the payment made - the milestones are structured around when they need money to move to the next step and how much they need (all very sensible and good business practice). How exciting are those RNSs going to be? It is all very early stage stuff. It is all important work, but does not reduce the risk very much at each point. Successful completion of stage 2 trials is the most significant point. Lots of new things make it through stage 1, that just means that the drug does not kill or injure people. Stage 2 is where you find out if it does more good than other things that are attempting to do the same thing. You can do your own research, but by far the majority (in the 90%+ bracket) do not make it through stage 2. From stage 2 there is then the problem of getting to full commercial exploitation, only then does money get made and that depends on take up and all sorts of other regulatory issues eg getting NICE to recommend its use - not a foregone conclusion even if it has passed stage 2 ok, other countries have their own systems for this. These risks and the potential rewards are all well explained in the admission document, which in my view is, although long and complicated in a number of areas, one of the best admission documents I have seen.

The proposed new directors have impressive CVs. I have no reason to doubt them. They have been granted options at the placing price, but did not buy in the placing. The fees being paid for their services are all in the admission document, at first look they do not seem to be excessive, but they are not insignificant either. It is good to see the non-execs on £10k a year, with options. A lot of AIM companies that do not generate cash (and this will not generate cash for many years - the admission document makes that clear) still take fees in the region of £40k per year and get consultancy payments for anything they do over and above turning up to board meetings. I know one of the Non Execs personally (the guy who has done the front end of the excellent admission document and is recommending you vote for all the resolutions) and if it were possible to clone him and put a clone on every AIM board, AIM would not be the cesspit it is.

I do not hold now and this sort of thing does not fit with my personal risk appetite. If it fits with yours then the very best of luck with your investment and the very best of luck to the Doctors and Professors involved in trying to find more effective cancer treatments.

sweet karolina
05/3/2016
12:26
Everyone should take the time to read the full admission document - it is one of the most comprehensive and well written ones I have seen - it is still a hard slog but worth it.

It explains the risks and potential rewards very well. It also explains the financial situation very well.



Read it all, not just the bits about how many $Bn the market could be worth.

sweet karolina
04/3/2016
11:21
Highlights
· SalvaRx operates in the field of cancer immunotherapy and its strategy is to identify, develop and finance further novel therapeutics that stimulate the immune system to fight cancer;

· SalvaRx owns 60.49 per cent. of iOx, a company which is developing under licence a series of compounds for cancer immunotherapy;

· SalvaRx's ownership of iOx gives the Company exposure to the fast-growing cancer immunotherapy market;

· iOx is focused on developing its pipeline of anti-cancer treatments based on invariant natural killer T cells and has a clinical trial sponsorship agreement with Oxford University who will conduct fund, or arrange funding for, the first Phase I/II in human trial;

· SalvaRx has a highly experienced management team who between them have a track record of developing novel drugs in cancer immunotherapy; and

· SalvaRx is actively screening acquisitions and investments in cancer immunotherapy and complementary areas of oncology.

Richard Armstrong, Non-Executive Chairman of 3Legs commented:

"We are very pleased to have agreed the acquisition of SalvaRx, subject to shareholder approval. The business has a strong and experienced management team in the cancer immunotherapy sector which is an exciting and fast growing market."

Ian Walters, CEO of SalvaRx commented:

"Joining AIM is a major step forward for SalvaRx and allows us to fund the iOx business through to its first in human trials sponsored by Oxford University. The listing will also raise our profile as we seek to build our immunotherapy business via further acquisitions and investment opportunities.

"The iOx scientists have developed significant insights into the role of natural killer T cells in stimulating a tumour specific immune response. We believe the compounds being developed by iOx could represent a major development in cancer treatment, especially when combined with existing immuno-oncology agents, with the hope of improving the care for many different types of cancer patients."

The Acquisition is of sufficient size to constitute a reverse takeover under the AIM Rules and is therefore subject to the approval of Independent Shareholders in General Meeting.

Trading on AIM in the Existing Ordinary Shares has been suspended since 4 November 2015 due to the Company not having completed an acquisition which constitutes a reverse takeover under the AIM Rules or otherwise having implemented its investing policy within 12 months of becoming an investing company. The suspension will remain in place pending the outcome of the General Meeting.

A circular, comprising an admission document ("Admission Document") and a notice of general meeting, will be posted to Shareholders today. Defined terms in this announcement have the same meaning as those in the Admission Document.

A copy of the circular may be downloaded from the Company's website at www.3legsresources.com

the stigologist
Chat Pages: Latest  12  11  10  9  8  7  6  5  4  3  2  1

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com